Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Uric Acid and CKD Progression Matures with Lessons for CKD Risk Factor Discovery.

Literature DB >> 33055190

Uric Acid and CKD Progression Matures with Lessons for CKD Risk Factor Discovery.

Oluwaseun Oluwo¹, Julia J Scialla^2,3.

Abstract

Entities: Chemical

Keywords: allopurinol; chronic kidney disease; epidemiology and outcomes; febuxostat; risk factors; uric acid

Mesh：

Substances：
Uric Acid

Year: 2020 PMID： 33055190 PMCID： PMC8011023 DOI： 10.2215/CJN.10650620

Source DB: PubMed Journal: Clin J Am Soc Nephrol ISSN： 1555-9041 Impact factor: 8.237

× No keyword cloud information.

11 in total

1. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk.

Authors: Marian Goicoechea; Soledad García de Vinuesa; Ursula Verdalles; Caridad Ruiz-Caro; Jara Ampuero; Abraham Rincón; David Arroyo; José Luño
Journal: Clin J Am Soc Nephrol Date: 2010-06-10 Impact factor: 8.237

2. Uric Acid and the Risks of Kidney Failure and Death in Individuals With CKD.

Authors: Anand Srivastava; Arnaud D Kaze; Ciaran J McMullan; Tamara Isakova; Sushrut S Waikar
Journal: Am J Kidney Dis Date: 2017-11-11 Impact factor: 8.860

Review 3. Are SGLT2 Inhibitors Ready for Prime Time for CKD?

Authors: Roberto Pecoits-Filho; Vlado Perkovic
Journal: Clin J Am Soc Nephrol Date: 2017-09-11 Impact factor: 8.237

Review 4. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation.

Authors: Richard J Johnson; George L Bakris; Claudio Borghi; Michel B Chonchol; David Feldman; Miguel A Lanaspa; Tony R Merriman; Orson W Moe; David B Mount; Laura Gabriella Sanchez Lozada; Eli Stahl; Daniel E Weiner; Glenn M Chertow
Journal: Am J Kidney Dis Date: 2018-02-27 Impact factor: 8.860

5. Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.

Authors: Alessandro Doria; Andrzej T Galecki; Cathie Spino; Rodica Pop-Busui; David Z Cherney; Ildiko Lingvay; Afshin Parsa; Peter Rossing; Ronald J Sigal; Maryam Afkarian; Ronnie Aronson; M Luiza Caramori; Jill P Crandall; Ian H de Boer; Thomas G Elliott; Allison B Goldfine; J Sonya Haw; Irl B Hirsch; Amy B Karger; David M Maahs; Janet B McGill; Mark E Molitch; Bruce A Perkins; Sarit Polsky; Marlon Pragnell; William N Robiner; Sylvia E Rosas; Peter Senior; Katherine R Tuttle; Guillermo E Umpierrez; Amisha Wallia; Ruth S Weinstock; Chunyi Wu; Michael Mauer
Journal: N Engl J Med Date: 2020-06-25 Impact factor: 91.245

6. Effect of Uric Acid Lowering on Renin-Angiotensin-System Activation and Ambulatory BP: A Randomized Controlled Trial.

Authors: Ciaran J McMullan; Lea Borgi; Naomi Fisher; Gary Curhan; John Forman
Journal: Clin J Am Soc Nephrol Date: 2017-03-20 Impact factor: 8.237

7. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.

Authors: Kenjiro Kimura; Tatsuo Hosoya; Shunya Uchida; Masaaki Inaba; Hirofumi Makino; Shoichi Maruyama; Sadayoshi Ito; Tetsuya Yamamoto; Yasuhiko Tomino; Iwao Ohno; Yugo Shibagaki; Satoshi Iimuro; Naohiko Imai; Masanari Kuwabara; Hiroshi Hayakawa; Hiroshi Ohtsu; Yasuo Ohashi
Journal: Am J Kidney Dis Date: 2018-09-01 Impact factor: 8.860

8. Effect of Uric Acid-Lowering Agents on Endothelial Function: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors: Lea Borgi; Ciaran McMullan; Ann Wohlhueter; Gary C Curhan; Naomi D Fisher; John P Forman
Journal: Hypertension Date: 2016-12-27 Impact factor: 10.190

9. Serum uric acid is associated with incident chronic kidney disease in middle-aged populations: a meta-analysis of 15 cohort studies.

Authors: Ping Zhu; Yan Liu; Lu Han; Gang Xu; Jian-min Ran
Journal: PLoS One Date: 2014-06-24 Impact factor: 3.240